About this trial
This Phase 3 study evaluates the safety and efficacy of cabozantinib in combination with atezolizumab versus the standard of care sorafenib in adults with advanced hepatocellular carcinoma (HCC) who have not received previous systemic anticancer therapy.
A single-agent cabozantinib arm will be enrolled in which subjects receive single agent cabozantinib in order to determine its contribution to the overall safety and efficacy of the combination with atezolizumab.
Adults with advanced hepatocellular carcinoma (HCC) who have not received previous systemic anticancer therapy
Where’s this trial being run?
St James’s Hospital
Can I join this study / trial?
The first thing you do is to talk to your doctor and/or the cancer trials research team in your hospital. The contact details for the cancer trials research units in Ireland is here.
Why not Print this page and bring it with you. It will help your doctor and research team advise you.Print this page
For more detailed informationClick Here
Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Subjects With Advanced hepatocellular carcinoma (HCC) Who Have Not Received Previous Systemic Anticancer Therapy
|Principal Investigator:||Prof Maeve Lowery (St James's Hospital)|
Ireland: June 2020
|Global Recruitment Target:||740|
|Ireland Recruitment Target:||5|